Polypeptide
Polypeptide, officially known as Polypeptide Group, is a leading global player in the biopharmaceutical industry, headquartered in Switzerland (CH). Founded in 1996, the company has established itself as a key provider of high-quality peptide-based therapeutics, serving major operational regions across Europe, North America, and Asia. Specialising in the development and manufacturing of peptides, Polypeptide offers a unique portfolio of services that includes custom peptide synthesis, contract development, and production. Their commitment to innovation and quality has positioned them as a trusted partner for pharmaceutical companies worldwide. Notable achievements include a robust pipeline of products and a reputation for excellence in peptide chemistry, making Polypeptide a prominent name in the biopharmaceutical landscape.
DitchCarbon Score
How does Polypeptide's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Polypeptide's score of 30 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Polypeptide's reported carbon emissions
In 2022, Polypeptide Group AG reported total carbon emissions of approximately 88,000,000 kg CO2e, with emissions distributed across Scope 1, Scope 2, and Scope 3. Specifically, Scope 1 emissions amounted to about 5,604,000 kg CO2e, primarily from stationary combustion (approximately 4,168,000 kg CO2e) and fugitive emissions (about 608,000 kg CO2e). Scope 2 emissions totalled around 4,323,000 kg CO2e, all from purchased electricity. The most significant contributor to their carbon footprint was Scope 3 emissions, which reached approximately 81,089,000 kg CO2e, with capital goods accounting for about 45,241,000 kg CO2e. Polypeptide has committed to near-term reduction targets, although specific numerical targets have not been disclosed. The company has not yet committed to a net-zero target. As a player in the pharmaceuticals, biotechnology, and life sciences sector, Polypeptide is actively working towards improving its sustainability practices in line with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | |
|---|---|
| Scope 1 | 5,604,000 |
| Scope 2 | 4,323,000 |
| Scope 3 | 81,089,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Polypeptide is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
